What's happening
This bill creates an emergency insulin program in New York to ensure affordable, rapid access to analog insulin for uninsured or underinsured individuals.
Why it matters
Creates a rapid response mechanism for insulin emergencies. By authorizing both patient-specific and non-patient-specific prescriptions, the bill empowers healthcare professionals and large pharmacies to dispense insulin quickly to those in urgent need, reducing the risk of life-threatening gaps in treatment.
Targets those most vulnerable to cost barriers. The program is explicitly designed for people with type 1 or insulin-dependent type 2 diabetes who are uninsured or underinsured, aiming to address health inequities and prevent dangerous medical outcomes due to lack of access.
Establishes broad distribution and oversight requirements. Large pharmacy chains and 340B-eligible medical facilities are required to participate and register as emergency insulin providers, ensuring widespread, statewide access and robust record-keeping, reporting, and oversight by the health department.
Funds program through public-private partnerships. The bill invites analog insulin manufacturers to contribute to a dedicated trust fund and participate in public-private partnerships, potentially leveraging industry resources to keep the program sustainable and costs low, including a cap of $100 for a 30-day supply for eligible recipients.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Provide Emergency Insulin Access
Plain English, a few words. Used as the page title.
Sponsors
History
- Referred to health
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Free Emergency Insulin Access
In Assembly Committee · Health · Sponsor Brian Cunningham
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
3222
2023-2024 Regular Sessions
IN SENATE
January 30, 2023
Introduced by Sens. RIVERA, GOUNARDES, KRUEGER, MYRIE, PERSAUD, SEPULVE- DA -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the public health law and the state finance law, in relation to an emergency insulin program
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The public health law is amended by adding a new article 28-CC to read as follows:
ARTICLE 28-CC
EMERGENCY INSULIN PROGRAM Section 2894. Emergency insulin program.
§ 2894. Emergency insulin program. 1. The commissioner is authorized and directed to establish an emergency insulin program to ensure that recipients of the program can access emergency supplies of analog insulins and related supplies. The commissioner shall immediately engage analog insulin manufacturers to support the state program and facilitate quick access to affordable analog insulins in emergency situations. The commissioner shall establish standards for approval of any emergency insulin program, and analog insulin prescribing, dispensing, distribution, and possession pursuant to this section which may include, but not be limited to, standards for program directors, appropriate clinical oversight, training, record keeping and reporting. The emergency insulin program shall, pursuant to an appropriation or sufficient funds in the emergency insulin program trust fund, be available to recipients no later than April first, two thousand twenty-four.
2. (a) As used in this section:
(i) "Analog insulins" means at a minimum short-acting, rapid-acting, intermediate and long acting insulin drugs approved by the Food and Drug Administration that, when administered, to certain recipients are lifesaving, and help avoid serious adverse effects associated with type one
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD05256-01-3
diabetes and in some limited cases type two diabetes, and other medications and supplies approved by the department for such purpose.
(ii) "Health care professional" means a person licensed, registered or authorized pursuant to title eight of the education law to prescribe prescription drugs.
(iii) "Pharmacist" means a person licensed or authorized to practice pharmacy pursuant to article one hundred thirty-seven of the education law.
(iv) "Recipient" means a person: (1) diagnosed with type one diabetes, or type two insulin dependent diabetes; and (2) who is at risk of experiencing serious adverse health effects due to a lack of analog insulins; and (3) who is uninsured or underinsured; or (4) an organization registered as an emergency insulin program pursuant to this section.
(b)(i) A health care professional may prescribe by a patient-specific or non-patient-specific prescription, dispense or distribute, directly or indirectly, analog insulins to a recipient.
(ii) A pharmacist may dispense analog insulins, through a patient-specific or non-patient-specific prescription pursuant to this paragraph, to a recipient.
(iii) The provisions of this paragraph shall not be deemed to require a prescription for any analog insulins that do not otherwise require a prescription; nor shall it be deemed to limit the authority of a health care professional to prescribe, dispense or distribute, or of a pharmacist to dispense, analog insulins under any other provision of law.
(iv) Any pharmacy with twenty or more locations in the state, and any facility established pursuant to article twenty-eight of this chapter which has a drug discount program authorized by section 340B of the Federal Public Health Service act 42 U.S.C § 256b shall pursue or maintain a non-patient-specific prescription with an authorized health care professional to dispense analog insulins to a recipient upon request, as authorized by this section; and register with the department as an emergency insulin program no later than January first, two thousand twentyfour.
3. Use or dispensing of analog insulins pursuant to this section shall be considered first aid or emergency treatment for the purpose of any statute relating to liability.
4. The commissioner shall immediately begin to work with analog insulin manufacturers in creating such program to ensure they are working with the state in a public-private partnership to support the state's streamlined emergency insulin program that may replicate patient support programs such manufacturers have. A manufacturer may contribute to the program through the emergency insulin program trust fund established pursuant to section ninety-five-1 of the state finance law.
5. The commissioner may establish a sliding scale for cost sharing for certain recipients which shall not exceed one hundred dollars for a thirty-day supply of analog insulins and related supplies.
6. The commissioner shall publish findings on the emergency insulin program including but not limited to the number of programs established, the number of recipients served, the types and amounts of analog insulins provided, the costs and savings associated with the program, and what public-private partnerships the state has facilitated to support this program to the governor and the chairs of the senate and assembly health committees within one year of the effective date of this article and every two years thereafter.
§ 2. The state finance law is amended by adding a new section 95-1 to read as follows:
§ 95-1. Emergency insulin program trust fund. 1. There is hereby established in the joint custody of the state comptroller and the commissioner of taxation and finance a special fund to be known as the "emergency insulin program trust fund".
2. Such fund shall consist of all monies appropriated for its purpose and all monies received, or to be paid into or credited to such fund by analog insulin manufacturers pursuant to subdivision four of section twenty-eight hundred ninety-four of the public health law. Nothing contained herein shall prevent the state from receiving assessments, grants, gifts or bequests for the purposes of the fund as defined in this section and depositing them into the fund according to law.
3. Monies of the fund shall be expended only to support the emergency insulin program established pursuant to article twenty-eight-CC of the public health law administered by the commissioner of health and for funding emergency access to analog insulins.
4. Monies shall be payable from the fund on the audit and warrant of the comptroller on vouchers approved and certified by the commissioner of health.
§ 3. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law and the state finance law, in relation to an emergency insulin program
Purpose
The purpose of this bill is to establish an emergency insulin program
Summary of specific provisions
Section 1 amends the public law by adding a new article 28-CC as it relates to establishing an emergency insulin program. This section allows the commissioner to establish an emergency insulin program to ensure that recipients of the program can access emergency supplies of analog insulin and other related supplies. The commission shall estab- lish standards of the program that include analog insulin prescribing, dispensing, distribution, and possession. Analog insulins, health care professionals, pharmacist, and recipient are all defined in this section for the purposes of this article. The use or dispensing of analog insu- lin, in accordance with this section, shall be considered first aid or emergency treatment for the purpose of any statute relating to liabil- ity.
Read the full memo (1,020 words)
Section 2 amends the finance law by adding a new section 95-1 as it relates to the emergency insulin program trust fund. The emergency insu- lin fund will be established in the joint custody of the state comp- troller and the commissioner of taxation and finance to support the emergency insulin program and fund emergency access to analog insulin.
Section 3 gives the effective date.
Justification
In December 2022, Governor Kathy Hochul declared a diabetes health emer- gency in New York State to tackle an epidemic that affects over 2 million state residents. When not managed properly, diabetes can have serious and debilitating health effects, including heart disease, kidney failure, blindness, and lower limb amputation. Severe complications of diabetes include Diabetic Ketoacidosis, also referred to as DKA, and even death. In recent years, New York has seen a significant increase in leg and foot amputation and eye disease. In New York City alone, there was a 356% increase in diabetes-related deaths during the early months of the COVID-19 pandemic.
Diabetes management is important in preventing further complications. Type 1 and some Type 2 diabetics depend upon insulin for their very survival. The recent increase in the cost of insulin made it difficult for some diabetics to obtain their necessary medication. When patients can't afford insulin, which can cost thousands of dollars even for those who are insured, they have resorted to rationing the little medication they can afford. In fact, one study found that one in four people with type 1 diabetes admitted to not taking their insulin as prescribed, or rationing, due to the cost.
This legislation creates an Emergency Insulin Program, modeled after New York State's Opioid Overdose Prevention Program which has expanded access to life-saving Naloxone to reverse an opioid overdose widely available in our state. Under the Emergency Insulin Program, individuals who are uninsured or underinsured would be able to get analog insulin through a non-patient specific prescription at certain pharmacies, including clinic and hospital pharmacies. The Department of Health would be able to establish a sliding scale for certain cost sharing, which would be capped at $100 per month for a thirty day supply of insulins and supplies.
The bill directs the Department of Health to immediately engage analog insulin manufacturers to support the state program and facilitate quick access to affordable analog insulin in emergency situations through a public private partnership to streamline existing patient support programs such manufactures have. The three manufacturers of analog insu- lin each have programs designed to help people access their products at a reduced rate or for free, however each program is different and advo- cates argue that they are difficult to access, especially in emergency situations. Recognizing that manufacturers want to make sure everyone can access the life-saving medications they offer to patents, this bill establishes an Emergency Insulin Program Trust fund to accept funds for the statewide program. Like New York's highly successful Opioid Overdose Prevention Program, this program would allow for non-patient specific prescriptions for analog insulins and utilize chain pharmacies and 340B pharmacies, which are able to provide the lowest cost medications, to distribute the insulins and supplies to recipients who qualify.
While it is true there are some types of human insulin that can be accessed over the counter and for a relatively low fee, these are often referred to as "dead in bed" insulin because they do not provide the level of support many type 1 and some type 2 diabetics require. These low cost human insulins are less commonly prescribed by doctors precise- ly because of their unpredictable rate of absorption, which can result in more frequent low and high blood sugars. They require more monitoring and more supplies and, according to advocates, when people transition from the newer and more costly analog insulins the risk of "dead in bed" syndrome is greatly increased.
In recent years, the Opioid Overdose Prevention Program has been expanded to provide access to life-saving medication in pharmacies, not just through community-based organizations. Like overdose, the risk of death from a lack of insulin occurs far too often and quickly. New York State must do all it can to make sure that diabetics who depend on insu- lin for their survival can access emergency supplies of analog insulin, just as we currently ensure that friends, families, and first responders are equipped with life-saving naloxone in case of an overdose. There is no question that a person who depends on daily insulin for their survival is at grave risk without timely access to affordable insulin. Nobody should die from rationing or running out of insulin, or from being forced to switch to less reliable human insulin. The Emergency Insulin Program can make sure New York, with the cooperation of manufac- turers of analog insulins, is doing all it can to ensure those in need can access this life-saving medication.
Legislative history
2019-2020: S7771/A10054 Gottfried 2021-2022: S4883/A194 Gottfried
Fiscal implications
To be determined, but potential savings as expensive hospitalizations as a result of severe adverse reactions from patients rationing or running out of insulin are avoided.
Effective date
This act shall take effect immediately
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.